[go: up one dir, main page]

MX2010003668A - Derivados de purina sustituidas con primidina. - Google Patents

Derivados de purina sustituidas con primidina.

Info

Publication number
MX2010003668A
MX2010003668A MX2010003668A MX2010003668A MX2010003668A MX 2010003668 A MX2010003668 A MX 2010003668A MX 2010003668 A MX2010003668 A MX 2010003668A MX 2010003668 A MX2010003668 A MX 2010003668A MX 2010003668 A MX2010003668 A MX 2010003668A
Authority
MX
Mexico
Prior art keywords
compounds
purine derivatives
substituted purine
pyrimidine substituted
disorders
Prior art date
Application number
MX2010003668A
Other languages
English (en)
Inventor
Meredith Williams
Harish Kumar Mysore Nagaraj
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of MX2010003668A publication Critical patent/MX2010003668A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se relaciona con compuestos de purina que son útiles como inhibidores de quinasas. Más particularmente, la presente invención se relaciona con compuestos de purina, los métodos para su preparación, las composiciones farmacéuticas que contienen estos compuestos y los usos de estos compuestos en el tratamiento de condiciones o trastornos proliferativos. Estos compuestos pueden ser útiles como medicamentos para el tratamiento de varias condiciones o trastornos proliferativos entre los que se incluyen tumores y cánceres así como otros trastornos o condiciones relacionados o asociados con las PI3 y/o TORm quinasas. (Ver fórmula I).
MX2010003668A 2007-10-05 2008-10-03 Derivados de purina sustituidas con primidina. MX2010003668A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97772007P 2007-10-05 2007-10-05
US7553208P 2008-06-25 2008-06-25
PCT/SG2008/000379 WO2009045175A1 (en) 2007-10-05 2008-10-03 Pyrimidine substituted purine derivatives

Publications (1)

Publication Number Publication Date
MX2010003668A true MX2010003668A (es) 2010-07-02

Family

ID=40030252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003668A MX2010003668A (es) 2007-10-05 2008-10-03 Derivados de purina sustituidas con primidina.

Country Status (16)

Country Link
US (3) US8247410B2 (es)
EP (1) EP2209786B1 (es)
JP (2) JP5479346B2 (es)
KR (3) KR101701109B1 (es)
CN (2) CN101889015B (es)
AU (1) AU2008307798B2 (es)
BR (1) BRPI0817503B8 (es)
CA (1) CA2701581C (es)
DK (1) DK2209786T3 (es)
ES (1) ES2406129T3 (es)
IL (2) IL204804A (es)
MX (1) MX2010003668A (es)
MY (1) MY150993A (es)
RU (2) RU2518098C2 (es)
WO (1) WO2009045175A1 (es)
ZA (1) ZA201003118B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
US8247410B2 (en) 2007-10-05 2012-08-21 Verastem Pyrimidine substituted purine derivatives
RS51975B (sr) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
WO2010005558A2 (en) 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
KR20110098908A (ko) * 2008-11-11 2011-09-02 엑스커버리 홀딩 컴퍼니 엘엘씨 ＰＩ3Ｋ/ｍＴＯＲ 키나제 억제제
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
EP2414362B1 (en) 2009-04-03 2014-06-11 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (s) inhibitors
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011078795A1 (en) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Bridged morpholino substituted purines
ES2986590T3 (es) 2010-06-14 2024-11-12 Scripps Research Inst Reprogramación de células hacia un nuevo destino
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
KR20140103135A (ko) * 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
KR101982912B1 (ko) * 2013-10-16 2019-09-10 상하이 잉리 파마슈티컬 컴퍼니 리미티드 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
SI3080103T1 (sl) * 2013-12-11 2018-11-30 Biogen Ma Inc. Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
WO2016109426A1 (en) * 2014-12-29 2016-07-07 Verastem, Inc. Oral dosing regimen of a dual mtor and pi3 inhibitor
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
SG11201706509QA (en) 2015-03-30 2017-09-28 Daiichi Sankyo Co Ltd 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
KR101589900B1 (ko) 2015-07-30 2016-01-29 강영만 바닥설치용 경계구
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
AR108665A1 (es) * 2016-06-02 2018-09-12 Celgene Corp Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania
EP3472147B1 (en) * 2016-06-16 2020-06-17 Janssen Pharmaceutica NV Azabenzimidazole derivatives as pi3k beta inhibitors
EP3550018B1 (en) 2016-12-02 2022-03-09 Daiichi Sankyo Company, Limited NOVEL ENDO-ß-N-ACETYLGLUCOSAMINIDASE
US11820782B2 (en) * 2017-03-31 2023-11-21 Ftg Bio Llc Salt forms of amino pyrazine purine based selective kinase inhibitor
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
KR20240097982A (ko) 2017-05-23 2024-06-27 메이 파마, 아이엔씨. 병용 요법
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.
EA202190880A1 (ru) * 2018-09-27 2021-06-28 Шанхай Инли Фармасьютикал Ко., Лтд Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение
TWI834784B (zh) * 2018-12-20 2024-03-11 美商Ｋｓｑ治療公司 經取代之吡唑并嘧啶及經取代之嘌呤以及其作為泛素特異性加工蛋白酶１ （ ｕ ｓ ｐ １ ） 抑制劑的用途
US11718624B2 (en) 2020-10-30 2023-08-08 KSQ Therapeutics, Inc. Solid state forms of substituted pyrazolopyrimidines and uses thereof
US20250145642A1 (en) * 2021-12-08 2025-05-08 Kineta, Inc. Bicyclic heteroarenes and methods of their use
WO2024041519A1 (zh) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其药物组合物及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617304A (en) * 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
DE59107440D1 (de) * 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
CA2294117A1 (en) 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
CA2320448C (en) * 1998-02-26 2005-02-01 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
PE20020613A1 (es) * 2000-07-19 2002-08-07 Novartis Ag Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
US7176312B2 (en) 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
EP1551410A2 (en) 2002-09-06 2005-07-13 Smithkline Beecham Corporation Novel compounds
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CN1735607B (zh) * 2002-11-21 2010-06-09 诺华疫苗和诊断公司 2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用
MXPA05005477A (es) * 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
US8247410B2 (en) 2007-10-05 2012-08-21 Verastem Pyrimidine substituted purine derivatives
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
EP2310391A1 (en) * 2008-06-27 2011-04-20 S*BIO Pte Ltd Pyrazine substituted purines
WO2010005558A2 (en) 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
EP2414362B1 (en) 2009-04-03 2014-06-11 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010114494A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders

Also Published As

Publication number Publication date
JP2014139159A (ja) 2014-07-31
BRPI0817503B8 (pt) 2021-05-25
EP2209786A1 (en) 2010-07-28
BRPI0817503B1 (pt) 2019-10-29
ZA201003118B (en) 2011-08-31
KR101701109B1 (ko) 2017-02-13
EP2209786B1 (en) 2013-02-27
RU2518098C2 (ru) 2014-06-10
ES2406129T3 (es) 2013-06-05
JP5885729B2 (ja) 2016-03-15
DK2209786T3 (da) 2013-06-03
AU2008307798A1 (en) 2009-04-09
KR20160116045A (ko) 2016-10-06
CN104119336B (zh) 2016-08-24
RU2681081C2 (ru) 2019-03-04
US20140066620A1 (en) 2014-03-06
US8247410B2 (en) 2012-08-21
IL235555A0 (en) 2014-12-31
CA2701581C (en) 2016-12-20
MY150993A (en) 2014-03-31
KR101643237B1 (ko) 2016-07-27
CN101889015B (zh) 2014-06-04
JP2010540625A (ja) 2010-12-24
JP5479346B2 (ja) 2014-04-23
IL204804A0 (en) 2010-11-30
IL235555B (en) 2019-08-29
US20100298319A1 (en) 2010-11-25
HK1203488A1 (en) 2015-10-30
RU2014110894A (ru) 2015-07-10
HK1145832A1 (en) 2011-05-06
CN101889015A (zh) 2010-11-17
US8609838B2 (en) 2013-12-17
IL204804A (en) 2014-11-30
US20130079512A1 (en) 2013-03-28
KR20100075609A (ko) 2010-07-02
CN104119336A (zh) 2014-10-29
AU2008307798B2 (en) 2013-10-03
BRPI0817503A2 (pt) 2015-05-05
RU2010117737A (ru) 2011-11-10
WO2009045175A1 (en) 2009-04-09
KR20150063171A (ko) 2015-06-08
CA2701581A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MX2010003668A (es) Derivados de purina sustituidas con primidina.
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
WO2012101654A3 (en) Novel triazine compounds
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
MD4590B1 (ro) Derivaţi macrociclici pentru tratamentul bolilor proliferative
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
GB201104267D0 (en) Pyrrolopyridineamino derivatives
MX347851B (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
AU2009282962A8 (en) Compounds as kinase inhibitors
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
WO2014016849A3 (en) Novel triazine compounds
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
GB201302704D0 (en) Therapeutic compounds
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
WO2008140420A3 (en) Pyrimidine derivatives
WO2009007753A3 (en) 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights